Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic-ecollection
Document type Journal Article
PubMed
32719739
PubMed Central
PMC7348058
DOI
10.3389/fonc.2020.00840
Knihovny.cz E-resources
- Keywords
- chemotherapy, glioblastoma, overall survival, radiotherapy, rapid early progression, real-world evidence,
- Publication type
- Journal Article MeSH
The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003-12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (p = 0.007). The interval between surgery and the start of radiotherapy (median 6.7 weeks) was not prognostically significant (p = 0.825). The median OS in the current cohort was about 2 months longer than in the historical control group treated 10 years ago (16 vs. 13.8 months) using the same Stupp's regimen. Taking into account differences in patient's characteristics between current and historical cohorts, age, extent of resection, and ECOG patient performance status adjusted HR (Stupp's regimen vs. RT alone) for OS was determined as 0.45 (p = 0.002).
Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Brno Czechia
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czechia
Department of Radiation Oncology Faculty of Medicine Masaryk University Brno Czechia
Department of Radiation Oncology Masaryk Memorial Cancer Institute Brno Czechia
Department of Radiology Masaryk Memorial Cancer Institute Brno Czechia
Faculty of Medicine Masaryk University Brno Czechia
Research Center for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czechia
See more in PubMed
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. . European organisation for research and treatment of cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. (2005) 352:987–96. 10.1056/NEJMoa043330 PubMed DOI
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. (2009) 10:459–66. 10.1016/S1470-2045(09)70025-7 PubMed DOI
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. (2005) 352:997–1003. 10.1056/NEJMoa043331 PubMed DOI
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. . Correlation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. (2008) 26:4189–99. 10.1200/JCO.2007.11.5964 PubMed DOI
Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. . Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. (2008) 9:29–38. 10.1016/S1470-2045(07)70384-4 PubMed DOI
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. . Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. (2017) 376:1027–37. 10.1056/NEJMoa1611977 PubMed DOI
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. . Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. (2012) 13:707–15. 10.1016/S1470-2045(12)70164-X PubMed DOI
Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. (2012) 13:916–26. 10.1016/S1470-2045(12)70265-6 PubMed DOI
Uhm JH, Porter AB. Treatment of glioma in the 21st century: an exciting decade of postsurgical treatment advances in the molecular era. Mayo Clin Proc. (2017) 92:995–1004. 10.1016/j.mayocp.2017.01.010 PubMed DOI
Kazda T, Dziacky A, Burkon P, Pospisil P, Slavik M, Rehak Z, et al. . Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards? Radiol Oncol. (2018) 52:121–8. 10.2478/raon-2018-0023 PubMed DOI PMC
Lakomy R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarová E, et al. . [Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003-2009]. Klin Onkol. (2011) 24:112–20. 10.14735/amko2011112 PubMed DOI
Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, et al. . MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. (2011) 102:2186–90. 10.1111/j.1349-7006.2011.02092.x PubMed DOI PMC
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. . Rindopepimut and temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double blind, international phase 3 trial. Lancet Oncol. (2017) 18:1373–85. 10.1016/S1470-2045(17)30517-X PubMed DOI
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. . Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. (2017) 318:2306–16. 10.1001/jama.2017.18718 PubMed DOI PMC
Sulman EP, Ismaila N, Armstrong TS, Sien C, Batchelor TT, Cloughesy T, et al. . Radiation therapy for glioblastoma: American society of clinical oncology clinical practice guideline endorsement of the American society for radiation oncology guideline. J Clin Oncol. (2017) 35:361–9. 10.1200/JCO.2016.70.7562 PubMed DOI
Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. . ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol. (2016) 118:35–42. 10.1016/j.radonc.2015.12.003 PubMed DOI
Chukwueke UN, Wen PY. Use of the response assessment in neuro-oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. (2019) 8:CNS28. 10.2217/cns-2018-0007 PubMed DOI PMC
R Core Team (2019). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; Available online at: https://www.R-project.org/
Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, et al. . Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. (2017) 19:1119–26. 10.1093/neuonc/nox025 PubMed DOI PMC
Gilbert MR, Dignan JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. . A randomized trial of bevacizumab for newly diagnosed glio-blastoma. N Engl J Med. (2014) 370:699–708. 10.1056/NEJMoa1308573 PubMed DOI PMC
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed gli-oblastoma. N Engl J Med. (2014) 370:709–22. 10.1056/NEJMoa1308345 PubMed DOI
Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, et al. . Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. (2010) 98:93–9. 10.1007/s11060-009-0067-2 PubMed DOI
Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, et al. . A randomized, open label phase 3 trial of nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. (2015) 51:522–32. 10.1016/j.ejca.2014.12.019 PubMed DOI
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. . Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. (2014) 15:1100–8. 10.1016/S1470-2045(14)70379-1 PubMed DOI
Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al. . Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. (2017) 19:965–75. 10.1093/neuonc/now257 PubMed DOI PMC
NIH U.S. National Library of Medicine, ClinicalTrials.gov A Study of ABT-414 in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1). Available online at: https://clinicaltrials.gov/ct2/show/NCT02573324 (Accessed December 1, 2019).
Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, et al. . Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers (Basel). (2019) 11:174. 10.3390/cancers11020174 PubMed DOI PMC
Wick W. TTFields: where does all the skepticism come from? Neuro Oncol. (2016) 18:303–5. 10.1093/neuonc/now012 PubMed DOI PMC
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. . Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients: the randomized, open-label CeTeG/NOA-09 trial. Lancet. (2019) 393:678–88. 10.1016/S0140-6736(18)31791-4 PubMed DOI
Kazda T, Bulik M, Pospisil P, Lakomy R, Smrcka M, Slampa P, et al. . Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging. Neuroimage Clin. (2016) 11:316–21. 10.1016/j.nicl.2016.02.016 PubMed DOI PMC
Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. (2008) 10:361–7. 10.1215/15228517-2008-008 PubMed DOI PMC
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. (2008) 26:2192–7. 10.1200/JCO.2007.14.8163 PubMed DOI
Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol. (2012) 35:284–9. 10.1097/COC.0b013e318210f54a PubMed DOI
Parvez K, Parvez A, Zadeh G. The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci. (2014) 15:11832–46. 10.3390/ijms150711832 PubMed DOI PMC
Belanova R, Sprlakova-Pukova A, Standara M, Janu E, Koukalova R, Kristek J, et al. . In silico study of pseudoprogression in glioblastoma: collaboration of radiologists and radiation oncologists in the estimation of extent of high dose RT region. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. (2019). [Epub ahead of print]. 10.5507/bp.2019.039 PubMed DOI
Wee CW, Kim E, Kim TM, Park CK, Kim JW, Choi SH, et al. . Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. J Neurooncol. (2017) 134:169–75. 10.1007/s11060-017-2505-x PubMed DOI
Merkel A, Soeldner D, Wendl C, Urkan D, Kuramatsu JB, Seliger C, et al. . Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials. J Neurooncol. (2017) 132:249–54. 10.1007/s11060-016-2362-z PubMed DOI PMC
Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA. Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. J Neurooncol. (2017) 134:213–9. 10.1007/s11060-017-2511-z PubMed DOI PMC
Palmer JD, Bhamidipati D, Shukla G, Sharma D, Glass J, Kim L, et al. . Rapid early tumor progression is prognostic in glioblastoma patients. Am J Clin Oncol. (2019) 42:481–6. 10.1097/COC.0000000000000537 PubMed DOI
Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions
